Translational Regulation of SARS-CoV-2 in response to viral S protein-induced signaling
Project Number5R21AI173187-02
Former Number1R21AI173187-01
Contact PI/Project LeaderMAZUMDER, BARSANJIT
Awardee OrganizationCLEVELAND STATE UNIVERSITY
Description
Abstract Text
Adopted folding of the RNA elements within the genomes of RNA viruses allows binding of host and viral
proteins and plays an essential role in host-virus interactions. However, the mechanistic insights on how these
RNA elements could sense the transduced signals from host cells are lacking for SARS-CoV-2. This project is
based on our recent discovery of a novel and structurally conserved RNA element within the ORF1a RNA and
S mRNA of SARS-CoV-2. Our studies showed that this element regulates the translation of viral proteins in
response to viral S protein-induced signaling in human lung cells. In prior studies, we identified a translational
silencing-dependent mechanism of controlling inflammation in myeloid cells. These studies showed that the
assembly of an L13a-dependent multi-protein RNA-binding complex (IFN-gamma-activated-inhibitor
of translation) or GAIT complex on the GAIT elements found in the 3' untranslated region (UTR) of target
mRNAs causing translational inhibition. Our studies also showed the physiological importance of this
mechanism as an endogenous defense against inflammation. Importance of the GAIT-like elements in human
responses to coronavirus and other respiratory pathogens is emerging from the published studies by us and
others. Our preliminary work presented in this proposal shows that treatment of human lung cells with SARS-
CoV-2 S protein activates a DAP kinase-dependent signaling mechanism causing the release of L13a from
large ribosomal subunit followed by the formation of L13a-dependent RNA-binding complex on “GAIT-like” viral
RNA elements of SARS-CoV-2, thus inhibiting translation. This led us to name these
elements virus activated inhibitor of translation (VAIT) elements. Together, these studies lead us to
hypothesize that ribosome-released form of L13a upon SARS-CoV-2 infection promotes the assembly of RNA-
binding complex on VAIT element of ORF1a RNA and S mRNA, which is biochemically and functionally distinct
from IFN-g-induced GAIT complex. The role of translational inhibition caused by the VAIT complex is testable.
We will test this hypothesis by pursuing the following two aims. Aim 1. To elucidate the composition of the
translation inhibitory VAIT RNP complex and identification of the upstream kinase in signaling. In this aim we
will use the combined approach of Gel filtration, RNA-affinity chromatography and mass spectrometry to
identify the subunits of the RNA-binding complex. Small molecule inhibitors and siRNA of the potential kinases
will be used to dissect the signaling aspect. Aim 2. To test the virological significance of VAIT element
mediated translational silencing. In this aim we will use extensive mutation in the VAIT element of the S gene
within the viral genomic RNA of the trans-complementation system to test the role of VAIT element-mediated
translational silencing in the intracellular expression of viral proteins and nucleic acid. Mechanistic insights on
VAIT element mediated translational silencing of SARS-CoV-2 RNAs may provide novel targets of small
molecule intervention and facilitate the development of next-generation mRNA vaccines.
Public Health Relevance Statement
Host cells play an important role in virus infection. When the SARS-CoV-2 virus infects lung cells, then the
activities of lung cells cause the inhibition of synthesis of two viral proteins, e.g., ORF1a and spike protein. This
proposal wants to uncover the mechanistic insights of this process.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
010841617
UEI
YKGMTXA2NVL6
Project Start Date
14-August-2023
Project End Date
31-July-2025
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$185,625
Direct Costs
$125,000
Indirect Costs
$60,625
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$185,625
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21AI173187-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21AI173187-02
Patents
No Patents information available for 5R21AI173187-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21AI173187-02
Clinical Studies
No Clinical Studies information available for 5R21AI173187-02
News and More
Related News Releases
No news release information available for 5R21AI173187-02
History
No Historical information available for 5R21AI173187-02
Similar Projects
No Similar Projects information available for 5R21AI173187-02